Zobrazeno 1 - 10
of 54
pro vyhledávání: '"William J, Sasiela"'
Autor:
Kristin K. Gillard, LeAnne Bloedon, John C. Grady-Benson, Alison Edwards, Sean Fahy, William J. Sasiela, Michael J. Louie, Paul D. Thompson
Publikováno v:
Cardiology and Therapy, Vol 13, Iss 3, Pp 575-591 (2024)
Abstract Introduction The prevalence of tendon rupture and tendinopathies (TRT) has not been determined in a large population of patients with atherosclerotic cardiovascular disease (ASCVD). We investigated TRT prevalence among patients with ASCVD an
Externí odkaz:
https://doaj.org/article/0e5b3f544f3c48cfb62e9708d3e1a0d1
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 3, Pp 789-798 (2022)
Abstract Bempedoic acid is an ATP citrate lyase inhibitor approved for the treatment of hypercholesterolemia. The objective of this phase I study was to assess the pharmacokinetics (PKs) and safety of bempedoic acid in 24 subjects with normal renal f
Externí odkaz:
https://doaj.org/article/006b738ed5a34d10829d6edcda6839ba
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2487-2496 (2021)
Abstract Bempedoic acid is an inhibitor of adenosine triphosphate–citrate lyase approved for use in adults with hypercholesterolemia. Nonclinical studies assessed binding to the human ether‐a‐go‐go–related gene (hERG) potassium channel in v
Externí odkaz:
https://doaj.org/article/d673bee841e24a1c9ed715ea6899fac6
Autor:
Erik S.G. Stroes, Harold E. Bays, Maciej Banach, Alberico L. Catapano, P. Barton Duell, Ulrich Laufs, G.B. John Mancini, Kausik K. Ray, William J. Sasiela, Yang Zhang, Antonio M. Gotto
Publikováno v:
Atherosclerosis, 373, 1-9. Elsevier Ireland Ltd
Background and aims: High-sensitivity C-reactive protein (hsCRP), a marker for atherosclerotic cardiovascular disease risk, is reduced by bempedoic acid. We assessed the relationship between changes in low-density lipoprotein cholesterol (LDL-C) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::054b1d8aa0f1ab6965a1b7fe7e7963c3
http://www.scopus.com/inward/record.url?scp=85151427440&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85151427440&partnerID=8YFLogxK
Autor:
R. Brett McQueen, Seth J. Baum, Michael J. Louie, William J. Sasiela, Aikaterini Bilitou, Hemal Shah, Beth Nash, Kristin K. Gillard, Kausik K. Ray
Publikováno v:
American Journal of Cardiovascular Drugs. 23:67-76
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9caf57c7702dd4bab5f5dc3c86457bb
https://doi.org/10.1007/s40256-022-00552-7
https://doi.org/10.1007/s40256-022-00552-7
Autor:
Satyawan B. Jadhav, Benny M. Amore, Howard Bockbrader, Ryan L. Crass, Sunny Chapel, William J. Sasiela, Maurice G. Emery
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics.
Population pharmacokinetics (popPK) of bempedoic acid and the popPK/pharmacodynamic (popPK/PD) relationship between bempedoic acid concentrations and serum low-density lipoprotein cholesterol (LDL-C) from baseline were characterized. A two-compartmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6383b40066b4c6a0843ac2c52bd9fd91
https://doi.org/10.1007/s10928-023-09864-w
https://doi.org/10.1007/s10928-023-09864-w
Publikováno v:
Clinical and Translational Science. 15:789-798
Bempedoic acid is an ATP citrate lyase inhibitor approved for the treatment of hypercholesterolemia. The objective of this phase I study was to assess the pharmacokinetics (PKs) and safety of bempedoic acid in 24 subjects with normal renal function o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b24965040dca7021beeaa11c0b0179b
https://doi.org/10.1111/cts.13202
https://doi.org/10.1111/cts.13202
Autor:
Gerald F. Watts, Satyawan B Jadhav, Sunny Chapel, Benny M. Amore, Alberico L. Catapano, P. Hugh R. Barrett, Ryan L Crass, Maurice G. Emery, Michael Kerschnitzki, William J. Sasiela
Publikováno v:
European Heart Journal - Cardiovascular Pharmacotherapy. 8:578-586
Aims Many patients are unable to achieve guideline-recommended LDL cholesterol (LDL-C) targets, despite taking maximally tolerated lipid-lowering therapy. Bempedoic acid, a competitive inhibitor of ATP citrate lyase, significantly lowers LDL-C with o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa82818bc1c931075bf655fc5640ac24
https://doi.org/10.1093/ehjcvp/pvab064
https://doi.org/10.1093/ehjcvp/pvab064
Autor:
Susan Kühnast, José W.A. van der Hoorn, Elsbet J. Pieterman, Anita M. van den Hoek, William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J. Wouter Jukema, Hans M.G. Princen
Publikováno v:
Journal of Lipid Research, Vol 55, Iss 10, Pp 2103-2112 (2014)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of
Externí odkaz:
https://doaj.org/article/53e1f0f319af41358683cedf9dce15c4
Autor:
Jacques Rey, Franck Poitiers, Tobias Paehler, Aurélie Brunet, A. Thomas DiCioccio, Christopher P. Cannon, Howard K. Surks, Jean‐Louis Pinquier, Corinne Hanotin, William J. Sasiela
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 6 (2016)
BackgroundAlirocumab undergoes target‐mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 (PCSK9). Statins increase PCSK9 levels; the effects of nonstatin lipid‐lowering therapies are unclear. Every‐4‐weeks dosing
Externí odkaz:
https://doaj.org/article/c518381745cb47939eff18a40e2c04b3